Overview: OncoPro TMB MSI Profile TestIntroduction: The OncoPro TMB MSI Profile Test assesses tumor mutation burden (TMB) and microsatellite instability (MSI) to guide cancer immunotherapy, improving treatment outcomes. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding immunotherapy decisions and improving outcomes in molecular pathology for patients with suspected cancers responsive to immunotherapy.
Other Names: TMB & MSI Assay, Immunotherapy Profile Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: TMB and MSI testing began in the 2010s with immunotherapy advancements. NGS methods improved diagnostic precision for immunotherapy guidance.
Purpose: Assesses TMB and MSI to guide cancer immunotherapy, evaluates patients with cancer symptoms, and improves treatment outcomes.
Test Parameters: 1. Tumor Mutation Burden & MSI
Pretest Condition: No fasting required. Collect tissue or whole blood. Report history of cancer symptoms or immunotherapy eligibility.
Specimen: Tissue (sterile container, 0.5-2 cma³), Whole Blood (EDTA, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document cancer symptoms, prior immunotherapy, or family history of cancer. Include current medications, especially checkpoint inhibitors.
Consent: Written consent required, detailing the tests purpose, TMB/MSI implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to assess TMB and MSI (e.g., MLH1, MSH2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for immunotherapy guidance.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: High TMB or MSI-high status guides immunotherapy, such as PD-1 inhibitors. Negative results may require alternative treatments.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: PD-L1 testing, tissue biopsy, or imaging (CT/MRI) to confirm immunotherapy eligibility.
Test Limitations: Not all cancers have high TMB or MSI; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Immunotherapy Guidelines, 2023; Journal of Clinical Oncology, Goodman AM, 2022.
